Different Metabolic Effects of Statins

This study has been completed.
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT01011127
First received: November 10, 2009
Last updated: October 4, 2010
Last verified: October 2010
  Purpose

The investigators hypothesize that pravastatin and rosuvastatin may have different metabolic effects in hypercholesterolemic patients.


Condition Intervention
Hypercholesterolemia
Drug: pravastatin, rosuvastatin

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Gachon University Gil Medical Center:

Study Start Date: December 2009
Study Completion Date: August 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
pravastatin Drug: pravastatin, rosuvastatin
rosuvastatin Drug: pravastatin, rosuvastatin

  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Sampling Method:   Probability Sample
Study Population

Hypercholesterolemia

Criteria

Inclusion Criteria:

  • Low-density lipoprotein cholesterol levels>130

Exclusion Criteria:

  • Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01011127

Locations
Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405-760
Sponsors and Collaborators
Gachon University Gil Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT01011127     History of Changes
Other Study ID Numbers: GMC-200914
Study First Received: November 10, 2009
Last Updated: October 4, 2010
Health Authority: South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:
Statins
Insulin resistance

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pravastatin
Rosuvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on April 16, 2014